Products
Verzistobart Biosimilar Monoclonal Antibody (TIM-3) for Research
Cat No.: GMP-Bios-INN-1456
Anti-HAVCR2/TIM3 therapeutic antibody (Pre-made Verzistobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Verzistobart (development codes INCAGN2390/INCAGN02390) is a monoclonal antibody targeting TIM-3 (HAVCR2). It is developed by Agenus and Ludwig Institute for Cancer Research and Incyte Corporation and University of Washington for Endometrial cancer, Squamous cell cancer, Malignant melanoma et al. in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1456-1mg | 1mg | 3090 |
| GMP-Bios-INN-1456-10mg | 10mg | |
| GMP-Bios-INN-1456-100mg | 100mg | |
| GMP-Bios-INN-1456-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Verzistobart biosimilar, Whole mAb, Anti-HAVCR2/TIM3 Antibody: Anti-TIM3/CD366/KIM-3/SPTCL therapeutic antibody |
| INN Name | Verzistobart |
| Target | HAVCR2/TIM3 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Agenus;Ludwig Institute for Cancer Research;Incyte Corporation;University of Washington |
| Conditions Approved | na |
| Conditions Active | Endometrial cancer;Squamous cell cancer;Malignant melanoma;Solid tumours;Cancer;Merkel cell carcinoma |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
